Fractyl
Marc Elia is the founder of M28 Capital, a healthcare sector investment fund. Prior to that, from January 2012 to September 2019, Mr. Elia served as a partner at Bridger Capital, an investment fund. He is on the Board of Directors of Adagio Therapeutics, Adimab, and SQZ Biotechnologies.
Mr. Elia holds a B.A. in economics from Carleton College.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Fractyl
2 followers
Fractyl aims to bring curative therapies to the large populations of patients with metabolic disease. With their innovative products, their goal is to truly shift the treatment paradigm for patients with metabolic disease by focusing on their root cause in the intestine to provide meaningful, transformative, benefits to restore patient health from metabolic diseases.